D. Graham

621 total citations
18 papers, 480 citations indexed

About

D. Graham is a scholar working on Rheumatology, Hematology and Surgery. According to data from OpenAlex, D. Graham has authored 18 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 9 papers in Hematology and 3 papers in Surgery. Recurrent topics in D. Graham's work include Rheumatoid Arthritis Research and Therapies (10 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Spondyloarthritis Studies and Treatments (8 papers). D. Graham is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Spondyloarthritis Studies and Treatments (8 papers). D. Graham collaborates with scholars based in United States, Australia and Canada. D. Graham's co-authors include J L Smith, Martin D. Lidsky, Theodore Rokkas, G. N. J. Tytgat, M F Dixon, Wai K. Leung, Douglas J. Veale, Robert Wołk, Thomas V. Jones and B.H. Thiers and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Investigative Dermatology and Endoscopy.

In The Last Decade

D. Graham

18 papers receiving 453 citations

Peers

D. Graham

SURGE

PHARM

GASTR

RHEUM

IMMUN

Sandra L. Sessoms United States

D Kleczkowski Sweden

M Shield United Kingdom

Federico Sopeña Spain

Angelo Dezi Italy

Huifang Xiong China

К. Tchernev Bulgaria

C Smyth Ireland

C. Brown United Kingdom

Ayumi Matsumoto Japan

Sandra L. Sessoms United States

D. Graham

195 ×0.8

SURGE

155 ×0.7

PHARM

90 ×0.8

GASTR

71 ×0.8

RHEUM

19 ×0.3

IMMUN

Citations per year, relative to D. Graham D. Graham (= 1×) peers Sandra L. Sessoms

Countries citing papers authored by D. Graham

Since Specialization

Citations

This map shows the geographic impact of D. Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Graham more than expected).

Fields of papers citing papers by D. Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Graham. The network helps show where D. Graham may publish in the future.

Co-authorship network of co-authors of D. Graham

This figure shows the co-authorship network connecting the top 25 collaborators of D. Graham. A scholar is included among the top collaborators of D. Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Graham. D. Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Purohit, Vivek S., J.L. Werth, D. Graham, & Timothy Nicholas. (2020). 512 Patient and disease characteristic predictors of systemic exposure to crisaborole. Journal of Investigative Dermatology. 140(7). S70–S70. 1 indexed citations

Bosch, Filip Van den, James Cheng‐Chung Wei, Peter Nash, et al.. (2020). OP0107 ETANERCEPT WITHDRAWAL AND RE-TREATMENT IN PATIENTS WITH INACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AT 24 WEEKS: RESULTS OF RE-EMBARK, AN OPEN-LABEL, PHASE IV TRIAL. Annals of the Rheumatic Diseases. 79. 70–70. 7 indexed citations

Ritchlin, Christopher T., Alexis Ogdie, Jon T. Giles, et al.. (2020). AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 79. 1717–1718. 2 indexed citations

Merola, Joseph F., Kim Papp, Peter Nash, et al.. (2020). Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies. Journal of the European Academy of Dermatology and Venereology. 34(12). 2809–2820. 15 indexed citations

Gladman, Dafna D., Christina Charles‐Schoeman, Iain B. McInnes, et al.. (2019). Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies. Arthritis Care & Research. 71(10). 1387–1395. 38 indexed citations

Soriano, Enrique R., Gustavo Citera, Mario H. Cardiel, et al.. (2018). FRI0099 Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. Annals of the Rheumatic Diseases. 77. 593–594. 3 indexed citations

Mease, Philip J., Joel M. Kremer, Stanley Cohen, et al.. (2018). SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. Annals of the Rheumatic Diseases. 77. 983–983. 7 indexed citations

Gladman, Dafna D., Christina Charles‐Schoeman, Iain B. McInnes, et al.. (2018). THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies. Annals of the Rheumatic Diseases. 77. 368–368. 1 indexed citations

Burmester, Gerd R, William F. C. Rigby, Ernest Choy, et al.. (2018). SAT0330 Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis. Annals of the Rheumatic Diseases. 77. 1030–1030. 3 indexed citations

10.

Kivitz, Alan, Oliver FitzGerald, Peter Nash, et al.. (2018). AB0902 Efficacy of tofacitinib by background methotrexate dose in patients with psoriatic arthritis: a post-hoc analysis of pooled data from 2 phase 3 trials. Annals of the Rheumatic Diseases. 77. 1575–1575. 2 indexed citations

11.

Heijde, D. van der, Dafna D. Gladman, Oliver FitzGerald, et al.. (2017). Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels : Results from a Phase 3 Clinical Study. Arthritis & Rheumatism. 69. 1 indexed citations

12.

Hall, Stephen, Oliver FitzGerald, D. van der Heijde, et al.. (2017). OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. Annals of the Rheumatic Diseases. 76. 141–142. 6 indexed citations

13.

Strand, Vibeke, Kurt de Vlam, Gladman Dd, et al.. (2017). AB0794 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies. Annals of the Rheumatic Diseases. 76. 1335–1336. 1 indexed citations

14.

Dore, Maria Pina & D. Graham. (2008). Gastritis, dyspepsia and peptic ulcer disease.. PubMed. 99(3). 323–33. 3 indexed citations

15.

Leung, Wai K. & D. Graham. (2001). Ulcer and Gastritis. Endoscopy. 33(1). 8–15. 19 indexed citations

16.

Silverstein, Fred E., et al.. (1995). MISOPROSTOL REDUCES SERIOUS GASTROINTESTINAL COMPLICATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING NSAIDS. 123(4). 241–249. 4 indexed citations

17.

Tytgat, G. N. J., et al.. (1993). THE ROLE OF INFECTIOUS AGENTS IN PEPTIC ULCER DISEASE. 6. 76–89. 83 indexed citations

18.

Smith, J L, et al.. (1987). Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.. PubMed. 82(11). 1153–8. 284 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact